ライフサイエンスコーパス: Kaplan-Meier estimate

1 aluable study cohort of 20 patients was 61% (Kaplan-Meier estimate).

2 tation after blinatumomab treatment was 65% (Kaplan-Meier estimate).

3 ssessed by the incidence of RBC transfusion (Kaplan-Meier estimate).

4 tion-free survival at four months was 90.2% (Kaplan-Meier estimate).

5 in other countries (P<0.001, on the basis of Kaplan-Meier estimates).

6 progression for responders of 86.6 weeks by Kaplan-Meier estimate.

7 d graft survival, and patient survival using Kaplan-Meier estimates.

8 entia risk per sum score was calculated with Kaplan-Meier estimates.

9 h time-to-event analysis ascertained through Kaplan-Meier estimates.

10 Survival analysis was performed using Kaplan-Meier estimates.

11 (PFS) and overall survival (OS) assessed by Kaplan-Meier estimates.

12 e to regression of seeds were estimated with Kaplan-Meier estimates.

13 absolute risks by calculating prevalence and Kaplan-Meier estimates.

14 OS was compared by Kaplan-Meier estimates.

15 Incidence was estimated using Kaplan-Meier estimates.

16 lyzed according to recipient BMI class using Kaplan-Meier estimates.

17 were assessed by Cox regression analysis and Kaplan-Meier estimates.

18 Cumulative stroke risk was calculated using Kaplan-Meier estimates.

19 g options had been lost in two participants (Kaplan-Meier estimate 0.7%) in the OT group and six (2.1

20 The Kaplan-Meier estimated 1-year rates of all-cause mortali

21 Kaplan-Meier-estimated 1-, 5-, 10-, and 15-year survival

22 basis of personalized cytogenetic profiles, Kaplan-Meier estimates (1, 3, and 5 years) for melanoma-

23 or renal failure (placebo, 75 events [60-day Kaplan-Meier estimate, 13.0%]; serelaxin, 76 events [13.

24 With median follow-up at 14.7 months, the Kaplan-Meier estimated 2-year survival rate was 79%.

25 stenting group (cumulative incidence, 24.6%; Kaplan-Meier estimate, 26.2%) and 45 patients in the end

26 Kaplan-Meier estimated 3-year survival rates from start

27 erectomy group (cumulative incidence, 26.9%; Kaplan-Meier estimate, 30.3%) (absolute difference in cu

28 n randomisation and 120 days, there were 34 (Kaplan-Meier estimate 4.0%) events of disabling stroke o

29 Kaplan-Meier estimated 5-year disease-specific survival

30 Kaplan-Meier estimated 5-year overall survival and disea

31 Kaplan-Meier estimated 5-year rates of target vessel rev

32 d ICH during 5197 person-years of follow-up (Kaplan-Meier estimated 5-year risk 15.8%, 95% CI 13.7-17

33 reated with alemtuzumab (66 of 133 patients, Kaplan-Meier estimate 51.6%, 95% CI 43.2-60.7%) than pat

34 Based on Kaplan-Meier estimates, 59% of patients in the interfero

35 The Kaplan-Meier-estimated 6-month transition rates were 5.1

36 or stroke were similar in the three groups (Kaplan-Meier estimates, 6.5% in group 1, 5.6% in group 2

37 h alemtuzumab were free of CDA at 36 months (Kaplan-Meier estimate 71.8%, 95% CI 63.1-78.8%) compared

38 and 750 of 8881 in the placebo group (3-year Kaplan-Meier estimates 8.1%vs 9.7%, HR 0.80, 95% CI 0.72

39 Graft survival was high (Kaplan-Meier estimates: 92.7%, 92.5%, and 92.5%), as was

40 Kaplan-Meier estimates (95% CIs) for the incidence of th

41 Kaplan-Meier estimated a higher event percentage than th

42 es in all-cause mortality were examined with Kaplan-Meier estimates, adjusted logistic regression, an

43 We constructed Kaplan-Meier estimates and applied parametric survival a

44 Kaplan-Meier estimates and Cox models were used to evalu

45 erculosis-related deaths were assessed using Kaplan-Meier estimates and Cox models.

46 Kaplan-Meier estimates and Cox proportional hazard regre

47 ata System database between 1988 and 1998 by Kaplan-Meier estimates and Cox proportional hazards mode

48 We used Kaplan-Meier estimates and Cox proportional hazards mode

49 Using Kaplan-Meier estimates and Cox proportional hazards mode

50 Kaplan-Meier estimates and Cox proportional hazards regr

51 We used Kaplan-Meier estimates and Cox regression to estimate an

52 inical and immunologic end points, by use of Kaplan-Meier estimates and Cox regression.

53 comes and graft survival were analyzed using Kaplan-Meier estimates and Cox univariate and multivaria

54 We compared overall survival using Kaplan-Meier estimates and equality of survival distribu

55 We used Kaplan-Meier estimates and log-rank tests to compare tim

56 Survival analyses were conducted using Kaplan-Meier estimates and multivariable Cox regression.

57 Both Kaplan-Meier estimates and observed relapse rates were a

58 Kaplan-Meier estimates and proportional hazards analysis

59 nary resuscitation organs was compared using Kaplan-Meier estimates and stratified log-rank test.

60 rates between the groups were compared with Kaplan-Meier estimates and the log-rank test.

61 and multivariate logistic regression models, Kaplan-Meier estimates, and Cox proportional hazards mod

62 noma-related mortality were calculated using Kaplan-Meier estimates, and Cox proportional hazards reg

63 lyses were performed using log-rank test and Kaplan-Meier estimates, and multivariate analyses were p

64 ions among indicators and the log-rank test, Kaplan-Meier estimates, and multivariate Cox proportiona

65 OS was assessed with Kaplan-Meier estimates, and the Mantel-Cox log-rank test

66 Survival curves based on Kaplan-Meier estimates are presented.

67 ut no controls were diagnosed with CD (15.2% Kaplan-Meier estimate at 10 years).

68 Kaplan-Meier estimates at 1 and 5 years were used to com

69 Kaplan-Meier estimates at 2 years showed statistically s

70 Kaplan-Meier estimates at 7 years post-treatment reveale

71 Primary patency per Kaplan-Meier estimates at day 365 was 82.3% for DCB vers

72 istry and were 91.5% and 83.2% at 5 years by Kaplan-Meier estimates based on linked United Network fo

73 By Kaplan-Meier estimates, CG-positive patients showed earl

74 ssion-free survival (PFS) were explored with Kaplan-Meier estimates, Cox regression, and random survi

75 t, Kruskal-Wallis, Spearman correlation, and Kaplan-Meier estimates; Cox regression models were perfo

76 At 3 years after coronary angiography, the Kaplan-Meier estimated cumulative percentages with event

77 f 5.8%(95%CI, -1.4%to 13.1%) [corrected].The Kaplan-Meier estimated cumulative percentages with event

78 The Kaplan-Meier estimated cumulative probability of virolog

79 Kaplan-Meier estimates demonstrated improved cumulative

80 Kaplan-Meier estimates demonstrated MACE rates at 1 year

81 cluding breast cancer, were calculated using Kaplan-Meier estimates, Fine and Gray competing-risks re

82 With a median follow-up of 39.7 months, the Kaplan-Meier estimate for 2-year overall survival was 98

83 Kaplan-Meier estimate for absence of metastatic disease

84 ls were collected every 6 months; the 4-year Kaplan-Meier estimate for incidence of HgbA1c levels >/=

85 Kaplan-Meier estimate for local control at 5 years was 7

86 The Kaplan-Meier estimate for local control was 85% at 3 yea

87 Kaplan-Meier estimate for melanoma-related metastasis in

88 The 24-month Kaplan-Meier estimate for orbital recurrence-free surviv

89 s with DCB were also superior to PTA per the Kaplan-Meier estimate for primary patency (89.0% versus

90 nts (age 67+/-16.2 years; 53.7% female), the Kaplan-Meier estimate for stroke/TIA recurrence within 1

91 The Kaplan-Meier estimate for the cumulative risk of extensi

92 The Kaplan-Meier estimates for 1-, 5-, and 10-year transplan

93 The Kaplan-Meier estimates for 1-year recipient survival wer

94 Graft survival rates were calculated using Kaplan-Meier estimates for both overall graft survival (

95 Kaplan-Meier estimates for both, patient-censored and de

96 Kaplan-Meier estimates for CABG and DES did not signific

97 9.6% when refCFVR </= 2.7 (P<0.001), whereas Kaplan-Meier estimates for cardiac mortality were 7.7% w

98 8-year Kaplan-Meier estimates for disease-free survival were 82

99 Endpoints included overall Kaplan-Meier estimates for hernia recurrence and postope

100 Overall, the 2-year Kaplan-Meier estimates for ocular survival, patient surv

101 8-year Kaplan-Meier estimates for overall survival were 91.8% (

102 iting times to transplant were obtained from Kaplan-Meier estimates for patients registered 1998-2000

103 The 10-year Kaplan-Meier estimates for RFS in arm A were 90.9% and 6

104 The Kaplan-Meier estimates for systemic metastasis in the me

105 Kaplan-Meier estimates for the PFS at 1, 5, and 10 years

106 Five- and 10-year metastasis-free Kaplan-Meier estimates for the recurrence-free group wer

107 Kaplan-Meier estimates for tumor recurrence in the 1995

108 and 7.2%, respectively, according to 2-year Kaplan-Meier estimates; hazard ratio with saxagliptin, 1

109 , vs. 25% in the placebo group, according to Kaplan-Meier estimates; hazard ratio, 0.36; P=0.003).

110 and 12.4%, respectively, according to 2-year Kaplan-Meier estimates; hazard ratio, 1.02; 95% CI, 0.94

111 an-Meier estimate] vs 151/8849 [2.1%, 3-year Kaplan-Meier estimate], HR 1.61, 95% CI 1.31-1.97; p<0.0

112 ied end point and 21% (95% CI, 7% to 26%) by Kaplan-Meier estimate in a post hoc analysis using metho

113 < 3 years), and 20% (95% CI, 10% to 37%) by Kaplan-Meier estimate in post hoc analysis using definit

114 to 1.48; P=0.43); event rates were based on Kaplan-Meier estimates in time-to-event analyses.

115 Event rates were based on Kaplan-Meier estimates in time-to-first-event analyses.

116 We compare cumulative incidence and Kaplan-Meier estimates in two series of mitral valve rep

117 The Kaplan-Meier estimated incidence of bleb-related infecti

118 By Kaplan-Meier estimates, iris nevus growth to melanoma oc

119 Clinical outcomes were analyzed with Kaplan-Meier estimates, log-rank comparisons, and Cox re

120 Kaplan-Meier estimated median duration of response was 1

121 with objective tumor regressions (31%), the Kaplan-Meier estimated median response duration was 2 ye

122 Kaplan-Meier estimated median time to progression (TTP)

123 In responders, Kaplan-Meier estimated median TTP was 12.6 months (range

124 of response (DR) have not been reached, but Kaplan-Meier estimated medians are 17.8 months (range, 5

125 The Kaplan-Meier estimated medians for duration of response,

126 By Kaplan-Meier estimates, metastasis in patients with ocul

127 Kaplan-Meier estimated mortality rates were 2.4% at 1 ye

128 Kaplan-Meier-estimated mortality was 3.2% at 30 days, 6.

129 Kaplan--Meier estimates of disease-free survival in pati

130 Kaplan--Meier estimates of disease-free survival stratif

131 dian, 91 months) after transplantation for a Kaplan-Meier estimate of 14% (95% confidence interval, 4

132 The Kaplan-Meier estimate of 2-year survival was fit to the

133 .5 to 11.6 (median, 2.8) years, for a 3-year Kaplan-Meier estimate of 58% (CI, 43%-73%).

134 atment was superior to short-term treatment (Kaplan-Meier estimate of difference 14.3% [5.1-23.6]; ha

135 .4% [95% CI 41.9-55.0] vs 56.4% [49.1-63.6]; Kaplan-Meier estimate of difference 7.9% [-1.9 to 17.7];

136 py group than in the standard-therapy group (Kaplan-Meier estimate of event-free survival [+/-SD]: 75

137 The Kaplan-Meier estimate of local recurrence in the conserv

138 The 10-year Kaplan-Meier estimate of LRR was 4.% (95% CI, 2.3% to 6.

139 The Kaplan-Meier estimate of median survival was 12.5 months

140 The Kaplan-Meier estimate of median time to disease progress

141 The Kaplan-Meier estimate of median waiting time to transpla

142 The Kaplan-Meier estimate of ocular survival at two years wa

143 The Kaplan-Meier estimate of overall survival (OS) for patie

144 The Kaplan-Meier estimate of overall survival at 3 years was

145 The Kaplan-Meier estimate of overall survival was 38%.

146 The Kaplan-Meier estimate of patients alive 5 years after re

147 The Kaplan-Meier estimate of patients free from corticostero

148 The Kaplan-Meier estimate of probability of CNS recurrence a

149 Only 1 of 24 patients remains alive and the Kaplan-Meier estimate of probability of survival at 1 ye

150 an follow-up of 24 (range, 3-36) months, the Kaplan-Meier estimate of progression (>/= 1.0 point EDSS

151 Kaplan-Meier estimate of relapse revealed patients with

152 relapse of CML following transplant (5-year Kaplan-Meier estimate of relapse, 20%; 95% confidence in

153 pients relapsed following transplant (5-year Kaplan-Meier estimate of relapse, 3%; 95% CI, 0% to 7%).

154 The Kaplan-Meier estimate of survival at five years was 57 p

155 The Kaplan-Meier estimate of survival at five years was 74 p

156 The Kaplan-Meier estimate of the 1-year event rate of the co

157 The Kaplan-Meier estimate of the 6-month incidence of CMV di

158 The Kaplan-Meier estimate of the cumulative incidence of rej

159 The Kaplan-Meier estimate of the cumulative proportion of su

160 Kaplan-Meier estimate of the incidence of TIA /stroke wi

161 The Kaplan-Meier estimate of the median duration of the resp

162 A Kaplan-Meier estimate of the median time to melanoma amo

163 The Kaplan-Meier estimate of the proportion of patients prog

164 The Kaplan-Meier estimate of the rate of the primary safety

165 The Kaplan-Meier estimate of the risk of relapse at the end

166 The Kaplan-Meier estimate of the risk of tuberculosis during

167 Kaplan-Meier estimate of time to disease progression in

168 The Kaplan-Meier estimate of total risk of pregnancy loss wa

169 Kaplan-Meier estimates of 12-year all-cause mortality we

170 Kaplan-Meier estimates of 3-year PFS were 43% (95% CI 36

171 The Kaplan-Meier estimates of 3-year relapse-free survival (

172 llow-up time of 46 months (range, 23 to 93), Kaplan-Meier estimates of 3.5-year OS for stage II, IIIA

173 Kaplan-Meier estimates of 5-year survival rates were 88%

174 Kaplan-Meier estimates of 6-month mortality declined fro

175 d placebo groups, respectively, resulting in Kaplan-Meier estimates of 77.2% (95% CI 71.87-82.51) of

176 aspirin was associated with similar 180-day Kaplan-Meier estimates of adjudicated composite GI event

177 One-year Kaplan-Meier estimates of adverse event-free survival (d

178 Kaplan-Meier estimates of composite efficacy failure-fre

179 Kaplan-Meier estimates of cumulative best rates of compl

180 Kaplan-Meier estimates of death at 1, 5, 10, and 20 year

181 Kaplan-Meier estimates of death at 5, 10, and 20 years w

182 At 30 months, the Kaplan-Meier estimates of DFS and OS from diagnosis were

183 At 4 years, the Kaplan-Meier estimates of DFS and OS from diagnosis were

184 Kaplan-Meier estimates of disease-free survival at 2 yea

185 The 18-month Kaplan-Meier estimates of disease-free survival were sig

186 int was demonstrated for Arm 2 versus Arm 1; Kaplan-Meier estimates of efficacy failure were 42.2% an

187 Kaplan-Meier estimates of event-free (EFS) and overall s

188 The Kaplan-Meier estimates of event-free survival at 8 years

189 Kaplan-Meier estimates of freedom from recurrent obstruc

190 Kaplan-Meier estimates of hard events were 0.5% versus 6

191 We produced Kaplan-Meier estimates of major adverse cardiovascular e

192 Kaplan-Meier estimates of median survival and descriptiv

193 Kaplan-Meier estimates of median time to progression in

194 After therapy, Kaplan-Meier estimates of metastasis at 1, 5, 10, and 20

195 After therapy, Kaplan-Meier estimates of metastasis at 5, 10, and 20 ye

196 The Kaplan-Meier estimates of mortality at day 60 did not di

197 Kaplan-Meier estimates of mortality for the whole study

198 310 deaths among patients without bleeding (Kaplan-Meier estimates of mortality, 4.5%, 10.0%, and 2.

199 In the development cohort, the Kaplan-Meier estimates of nursing home placement through

200 Two-year Kaplan-Meier estimates of ocular survival and disease-fr

201 The 36-month Kaplan-Meier estimates of ocular survival were 83.3% (95

202 Analyses of Kaplan-Meier estimates of OS by response and null Martin

203 Five-year Kaplan-Meier estimates of overall survival among patient

204 Four-year Kaplan-Meier estimates of patient survival in the Astagr

205 In the treatment group, Kaplan-Meier estimates of patient survival were 90.6% at

206 Kaplan-Meier estimates of patients alive and progression

207 Week 24 Kaplan-Meier estimates of PTDM were similar for arm 1 ve

208 In both validation cohorts, the Kaplan-Meier estimates of recurrence confirmed that both

209 Kaplan-Meier estimates of recurrence for 1, 2, and 5 yea

210 ed the effect of selection for tracing using Kaplan-Meier estimates of reengagement among all patient

211 Kaplan-Meier estimates of risk of relapse at 36 weeks we

212 Kaplan-Meier estimates of seven-year survival for the to

213 s. 95%; p = 0.03 by log-rank test) on 5-year Kaplan-Meier estimates of survival after surgical AVR.

214 Kaplan-Meier estimates of survival and event-free surviv

215 Kaplan-Meier estimates of survival and time to recurrenc

216 Kaplan-Meier estimates of survival probability did not d

217 Kaplan-Meier estimates of survival were 82%, 76%, 68%, a

218 Visual acuity, Kaplan-Meier estimates of survival, local control, metas

219 gic data of 125 patients were compared using Kaplan-Meier estimates of survival.

220 Kaplan-Meier estimates of the actuarial incidence, which

221 Kaplan-Meier estimates of the cumulative incidence were

222 Kaplan-Meier estimates of the cumulative probabilities o

223 Kaplan-Meier estimates of the cumulative probability of

224 mponent of the dual-design study, the 5-year Kaplan-Meier estimates of the incidence of arrhythmic ev

225 mponent of the dual-design study, the 5-year Kaplan-Meier estimates of the incidence of arrhythmic ev

226 Five-year Kaplan-Meier estimates of the incidence of the primary e

227 103 (8.2 percent) in the control group; the Kaplan-Meier estimates of the likelihood of freedom from

228 After 12 months of follow-up, Kaplan-Meier estimates of the mean (+/-SE) rates of even

229 Kaplan-Meier estimates of the OS rate at 1, 3, and 5 yea

230 Kaplan-Meier estimates of the primary endpoint across gr

231 Randomization to PPI therapy reduced 180-day Kaplan-Meier estimates of the primary GI endpoint in low

232 Incidence rates and Kaplan-Meier estimates of the probability of developing

233 The Kaplan-Meier estimates of the rates of distant recurrenc

234 Kaplan-Meier estimates of the rates of the primary end p

235 Kaplan-Meier estimates of the recrudescence rate in the

236 Kaplan-Meier estimates of the stroke rate at days 2, 7,

237 two-tailed) for categorical comparisons, and Kaplan-Meier estimates of time to events of interest.

238 Kaplan-Meier estimates of time to regression and ocular

239 sation and adverse events were calculated as Kaplan-Meier estimates of time to the first event.

240 The Kaplan-Meier estimates of transplant-free survival from

241 By year 10, 93% (Kaplan-Meier estimate) of probands had recovered from th

242 A cumulative proportion of 85% (Kaplan-Meier estimate) of the 380 recovered subjects exp

243 The cumulative incidence (Kaplan-Meier estimate) of the primary end point was 5.5%

244 bjects experienced a recurrence, as did 58% (Kaplan-Meier estimate) of those who remained well for at

245 h test/validation set-defined cut points and Kaplan-Meier estimated outcome measures of 5-year overal

246 At 5 years, the Kaplan-Meier-estimated overall survival rates were 74% (

247 Kaplan Meier estimated patient and graft survivals for a

248 According to Kaplan-Meier estimates, patients with AT <40% of predict

249 duced symptomatic herpes-simplex infections (Kaplan-Meier estimates: placebo 36 [23.5%] of 154; ganci

250 hen applied to nonfatal events, however, the Kaplan-Meier estimates probabilities as if the patients

251 se outcomes than patients with complete PVD (Kaplan-Meier estimated probability and standard error, 1

252 At 2 years, Kaplan-Meier-estimated progression-free survival was 73%

253 Kaplan-Meier estimated proportions of treatment failure

254 rsonalized cytogenetic profiles, with 5-year Kaplan-Meier estimates ranging from 4% with chromosomes

255 The Kaplan-Meier estimated recovery rate from dysthymic diso

256 Kaplan-Meier estimates results were similar in the per-p

257 Kaplan-Meier estimates showed a reduction in the seconda

258 as not powered for survival as an end point, Kaplan-Meier estimates showed a trend in overall surviva

259 Kaplan-Meier estimates showed that 10-year adverse liver

260 Kaplan-Meier estimated survival and event-free survival

261 Based on the Kaplan-Meier estimate, the probability of grade II-IV ac

262 mortality analyses were inconsistent: using Kaplan-Meier estimates, the persons with RA in prepaid g

263 Based on the results of Kaplan-Meier estimates, the time between baseline transt

264 ith secondary enucleation and metastases and Kaplan-Meier estimates to assess the probability of meta

265 Using Kaplan-Meier estimates to compare outcome, 30-day surviv

266 ther day of monitored hospitalization, using Kaplan-Meier estimates to determine the rate of resuscit

267 The Kaplan-Meier-estimated TTP was 6.8 months (range, 1.1 to

268 us the placebo group (241/8880 [3.4%, 3-year Kaplan-Meier estimate] vs 151/8849 [2.1%, 3-year Kaplan-

269 accumulation, and median overall survival by Kaplan-Meier estimate was not reached.

270 utero transmission of HIV-1 on the basis of Kaplan-Meier estimates was 5.7% (93 infants), with no si

271 ly, the cirrhosis-free actuarial survival by Kaplan-Meier estimates was significantly diminished in t

272 Three-year rates by Kaplan-Meier estimate were 72% (95% CI, 56% to 84%) for

273 eiving placebo had elective surgical repair (Kaplan-Meier estimates were 16.1% for those receiving do

274 doresection groups, respectively, the 5-year Kaplan-Meier estimates were as follows: overall survival

275 Kaplan-Meier estimates were calculated for recurrences a

276 Kaplan-Meier estimates were plotted for disease-free sur

277 Kaplan-Meier estimates were used for OS analyses.

278 Kaplan-Meier estimates were used to assess graft surviva

279 iables, t test for continuous variables, and Kaplan-Meier estimates were used to describe events.

280 Kaplan-Meier estimates were used to investigate time to

281 mated "freedom of incisional hernia" curves (Kaplan-Meier estimate) were significantly different acro

282 Relapse rates (Kaplan-Meier estimates) were lower among the patients wh

283 ll receiving tamoxifen alone; Cox models and Kaplan-Meier estimates with inverse probability of censo

284 th vorapaxar versus 28 of 8849 (0.4%, 3-year Kaplan-Meier estimate) with placebo (p=0.076).

285 ccurred in 43 of 8880 patients (0.6%, 3-year Kaplan-Meier estimate) with vorapaxar versus 28 of 8849